Irregular heartbeats can signal AFib. Early detection and appropriate treatments help manage it and protect long-term heart health.

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

IT’S the most wonderful time of the year – but also the most stressful. With endless shopping lists, family dramas and a ...